Balabanski Lubomir, Antov Georgi, Dimova Ivanka, Ivanov Samuil, Nacheva Maria, Gavrilov Ivan, Nesheva Desislava, Rukova Blaga, Hadjidekova Savina, Malinov Maxim, Toncheva Draga
Genomic Laboratory, Malinov Hospital, 1680 Sofia;
Bulgarian Academy of Sciences, Institute of Genetics 'Academician Doncho Kostov', 1113 Sofia;
Mol Clin Oncol. 2014 May;2(3):435-439. doi: 10.3892/mco.2014.251. Epub 2014 Feb 4.
Breast cancer is currently the most common type of cancer in females. The majority of the hereditary forms of breast cancer are caused by mutations in the and genes, whose main function is the DNA repair of double-strand breaks. Genetic testing of females with a family history of breast cancer is recommended to determine their hereditary predisposition for this type of cancer. The variants with no clear clinical significance may represent a diagnostic challenge when performing targeted resequencing. In this study, DNA samples were obtained from 24 breast cancer patients (mean age, 35±10 years) with a positive family history and from 71 age-matched healthy controls. Informed consent was obtained from all the subjects. Sequence-targeted and libraries were prepared using the TruSeq Custom Amplicon method and sequenced on the Illumina MiSeq system. A wide range of variants were identified in the and genes. Two pathological/presumably pathological variants were detected in the breast cancer patient group: a mutation in at the chromosomal (chr) position chr13:32890665, which affected the first position of the 5' splice region following exon 2; and a mutation in at chr17:41219635, causing an in-frame triple nucleotide deletion of valine 1688 (8.3%). In the patient and control groups, 7 likely polymorphic variants and 13 common variants were detected in the and genes. To the best of our knowledge, this study was the first to identify 3 common polymorphisms in characteristic solely of the Bulgarian population, including chr13:32973737, T/-, a single-nucleotide polymorphism (SNP) within the 3'-UTR of exon 27; chr13:32973280, A/-, a mononucleotide deletion within the 5'-UTR of exon 27; and chr13:32973924, T/-, a mononucleotide deletion downstream of the gene sequence. To the best of our knowledge, this study was the first to apply next-generation sequencing of the and genes in a Bulgarian population, prompting further investigation for local founder mutations and variants characteristic for this particular region.
乳腺癌是目前女性中最常见的癌症类型。大多数遗传性乳腺癌是由BRCA1和BRCA2基因的突变引起的,其主要功能是修复双链断裂的DNA。建议对有乳腺癌家族史的女性进行基因检测,以确定她们患这种癌症的遗传易感性。在进行靶向重测序时,临床意义不明确的变异可能带来诊断挑战。在本研究中,从24名有阳性家族史的乳腺癌患者(平均年龄35±10岁)和71名年龄匹配的健康对照者中获取了DNA样本。所有受试者均签署了知情同意书。使用TruSeq Custom Amplicon方法制备了针对BRCA1和BRCA2的序列靶向文库,并在Illumina MiSeq系统上进行测序。在BRCA1和BRCA2基因中鉴定出了多种变异。在乳腺癌患者组中检测到两个病理性/可能病理性的变异:一个位于染色体(chr)位置chr13:32890665的BRCA1突变,影响外显子2后5'剪接区域的第一个位置;另一个位于chr17:41219635的BRCA2突变,导致缬氨酸1688的框内三核苷酸缺失(8.3%)。在患者组和对照组中,在BRCA1和BRCA2基因中检测到7个可能的多态性变异和13个常见变异。据我们所知,本研究首次在保加利亚人群中鉴定出仅在该人群中特有的BRCA1基因的3个常见多态性,包括chr13:32973737,T/ -,外显子27的3'-UTR内的单核苷酸多态性(SNP);chr13:32973280,A/ -,外显子27的5'-UTR内的单核苷酸缺失;以及chr13:32973924,T/ -,基因序列下游的单核苷酸缺失。据我们所知,本研究首次在保加利亚人群中对BRCA1和BRCA2基因应用下一代测序,促使对该特定区域特有的本地奠基者突变和变异进行进一步研究。